1760 Paon-Fu-Chin
Paon-Fu-Chin announced that the active pharmaceutical ingredient (API) Ferric Citrate for its kidney disease drug 'Nephoxil' has been approved by the NMPA in China.
📋 Article Processing Timeline
- 📰 Published: May 22, 2026 at 06:31
- 🔍 Collected: May 22, 2026 at 06:31 (0 min after Published)
- 🤖 AI Analyzed: May 31, 2026 at 21:27 (230h 56m after Collected)
Paon-Fu-Chin Biotechnology Co., Ltd. announced on May 21, 115, that the active pharmaceutical ingredient (API) Ferric Citrate for its new kidney disease drug, Nephoxil 500mg Capsule, has been approved by the National Medical Products Administration (NMPA) of China. This approval helps strengthen the company's API supply chain in the Chinese market and deepens its vertical integration strategy. This approval is separate from the drug product (capsule) approval announced on April 27, 115. New drug development involves risks, and investors should exercise caution.
FAQ
What is the main product of Paon-Fu-Chin?
The kidney disease drug 'Nephoxil'.